Ever since the publication of the Puget Sound pharmacosurveillance study in 1995, 1 there has been a continuing debate on the effectiveness or safety of the calcium channel blockers (CCBs) in the treatment of hypertension and heart disease. Various retrospective case-control studies had raised the possibility that these drugs may cause haemorrhage, suicide, cancer and excess cardiovascular morbidity and mortality. 2 Several observational studies and some individual randomised trials in hypertension have even suggested that, compared with other drugs, CCBs may be associated with a higher risk of coronary events, despite similar blood pressure control.
Many of these anxieties seemed to have been allayed by the placebo-controlled SYST-EUR Trial 3 where the CCB, nitrendipine, bought about a major reduction in stroke and a large but nonsignificant fall in heart attacks, with no excess of cancer of haemorrhage. Similarly, the use of the CCB, felodipine, was beneficial in the HOT study. 4 Was the debate over? So it seemed, but the focus of the argument changed slightly. No one doubted that CCBs were better than placebo, but how do they compare with other agents? The STOP-H2 trial perported to show evidence of equivalence of calcium channel blockers (felodipine or isradipine) with the older agents (diuretics and beta-blockers) and was deemed by a Lancet commentary to be 'a draw'. 5, 6 However, there was still the tendency for the CCBs to be 'slightly better' than other agents at preventing stroke but to be 'slightly less effective' at preventing myocardial infarction and heart failure, with no difference in all-cause mortality. Two more trials with CCBs which were published in 2000 (INSIGHT and NORDIL) broadly produced similar findings but statistical and methodological considerations limited Correspondence: Dr GYH Lip, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. E-mail: g.y.h.lipȰbham.ac.uk the confidence of any one study to be sure of these such differences. 7, 8 Then as the millennium year ground to its sodden halt (in England at least) came a 'rush' of metaanalyses. To highlight a few, The Lancet published two papers on 9 December 9,10 and a 'mini' metaanalysis in their correspondence columns on 2nd December. 11 Another appeared in the British Journal of Cardiology in November. 12 There probably have been many others. Perhaps meta-analyses begat further meta-analyses.
The Blood Pressure Lowering Treatment Trialists' Collaboration is a programme of overviews of randomised trials which was established to investigate the effects of angiotensin-converting enzyme (ACE) inhibitors, CCBs, and other blood pressurelowering drugs on mortality and major cardiovascular morbidity. 9 Their overview of placebo-controlled trials of ACE inhibitors (four trials, 12 124 patients mostly with coronary heart disease) revealed reductions in stroke (30% [95% CI 15-43]), coronary heart disease (20% [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] ), and major cardiovascular events (21% [14 -27] ), which the metaanalysis of placebo-controlled trials of CCBs (two trials, 5520 patients mostly with hypertension) showed reductions in stroke (39% [15-56]) and major cardiovascular events (28% ). In the overview of trials comparing blood pressure-lowering strategies of different intensity (three trials, 20 408 patients with hypertension), there were reduced risks of stroke (20% ), coronary heart disease (19% [2-33]), and major cardiovascular events (15% [4 -24] ) with more intensive therapy. In the trials that compared CCB-based regimens with diuretic-based or beta-blocker-based regimens, patients assigned CCB-based therapy had a significant 13% lower risk of stroke (95% CI 2-23) than among those assigned diuretic-based or betablocker-based therapy. Additionally, there was a 12% greater risk of coronary heart disease events of borderline significance (0-26) amongst those assigned CCB-based therapy.
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The meta-analysis by Psaty et al 10 of nine eligible trials (27 743 participants), found that CCBs and other drugs achieved similar control of both systolic and diastolic blood pressure. Compared with patients assigned diuretics, beta-blockers, ACE inhibitors, or clonidine (n = 15 044), those assigned CCBs (n = 12 699) had a significantly higher risk of acute myocardial infarction (odds ratio 1.26 [95% CI 1.11-1.43], P = 0.0003), congestive heart failure (1.25 [1.07-1.46], P = 0.005), and major cardiovascular events (1.10 [1.02-1.18], P = 0.018). There was no significant difference for the outcomes of stroke and all-cause mortality.
The 'mini' meta-analysis of the INSIGHT, NORDIL and STOP-H2 trials 11 also showed a trend in favour of CCBs for cerebrovascular events (with a 14.7% reduction), and in favour of diuretics and betablockers for coronary events, with CCBs use resulting in a 20% increase in myocardial infarctions. In the 'solid' meta-analysis of eight trials by Rafflenbeul, 12 for the end point of acute myocardial infarction, there was a relative difference of 19% in favour of the diuretics, a 14% reduction in stroke favouring CCBs (vs diuretics/beta-blockers), whilst heart failure end points were no different.
These overviews, armed with large numbers, seem to confirm the same trends of the three major trials, that there was no difference between CCBs and other therapies on all-cause mortality, but a trend, which reaches statistical significance, for an inferior effect on heart disease and a superior effect on stroke. It is clear that treating blood pressure is beneficial, with strong evidence of benefits of ACE inhibitors and CCBs by the overviews of placebo-controlled trials. If the question is no longer 'do we treat hypertension?', but 'how to treat?' and 'who to treat?', some uncertainties arise. The meta-analyses suggest that there is weaker evidence of differences between treatment regimens of differing intensities and of differences between treatment regimens based on different drug classes. The meta-analysis by Psaty et al 10 even goes as far as suggesting that CCBs are inferior to other types of antihypertensive drugs as first-line agents in reducing the risks of several major complications of hypertension, and conclude that 'the longer-acting calcium antagonists cannot be recommended as first-line therapy for hypertension'.
Because meta-analyses look impressive, clinicians tend to believe them, but in fact they have many problems. Some of the trials included were designed to demonstrate drug equivalence, whilst others hoped to detect drug superiority. Some were open label studies with the risk of bias in randomisation. There were also major differences in the methods of all trials included. Furthermore, the meta-analyses themselves may be prone to bias as to which end points are examined. There is also the problem that they rely heavily on the larger trials, some of which can be criticised for their design. Finally, the biggest problem is that meta-analyses do not take into account the possible influences of other drugs used as second-line agents. In reality, more than half of all hypertensive patients need an additional drug, and a third require three drugs or more, to bring about adequate control of blood pressure.
Perhaps one may extend the debate by speculating on the mechanisms whereby the CCB's may differ from other antihypertensive agents, either benefically or adversely.
2, 13 The CCB's might be proarrhythmic, pro-haemorrhagic and may also cause coronary steal; they may also encourage apoptosis and activate the renin system. However, there are equal arguments in their favour, particularly as they may be antithrombotic. Sadly, laboratory-based scientists can provide theoretical mechanisms hereby anything might happen and other scientists can equally speculate why the same thing might not happen.
As with the last calcium channel blocker crises, there will be some anxiety amongst hypertensive patients when the 'anti-CCB' papers are reported in the newspapers or become available on the INTER-NET. This also follows on from the recent concerns over the use of doxazosin in the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT) study, with an increased risk of heart failure and stroke.
14 Clinicians have to have a sensible answer when questioned by their patients about the pros and cons of their antihypertensive therapy. Perhaps the best response is to emphasise that the highest priority is to control the blood pressure, and that there are subtle differences in outcome comparing the CCB's with other agents, but these are very controversial and may be unproven. We await the results of proper prospective randomised trials, such as ALLHAT and ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) with increased interest.
